Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895189 · ClinicalTrials.gov registry record
Yale COVID-19 Recovery Study
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 16
- Enrollment target
NCT04895189: Completed study, sponsored by Yale University.
NCT04895189 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04895189 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The general purpose of the study is to determine the change in immune responses in people with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) after vaccination. PASC is a disabling, heterogeneous condition in which people have persistent or emerging symptoms months after an initial SARS-CoV-2 infection, (the virus that causes coronavirus disease 2019, or COVID-19. Specifically, the purpose is to enroll participants suffering from moderate-to-severe PASC prior to vaccination and to measure participants' immune and symptom profiles both before and after vaccination. This study is primarily descriptive.
Primary Outcome
The primary outcome for the study is whether people's overall health condition improves, does not change, or worsens after receiving the COVID-19 vaccine. This outcome will be measured with the question in Surveys 2-4: "Would you say that your overall health, as compared to your health before the vaccine, is worse, better, or the same?" The number of participants within each group will be reported.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2025-05-09 |
What the finished NCT04895189 record still lists
NCT04895189 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT04895189 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04895189 about?
NCT04895189 is a clinical study titled "Yale COVID-19 Recovery Study". The general purpose of the study is to determine the change in immune responses in people with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) after vaccination. PASC is a disabling, heterogeneous condition in which people have persistent or emerging symptoms months after an initial SARS-CoV-2 in...
What is the current status of trial NCT04895189?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2021-05-03. Estimated completion is 2025-05-09.
What interventions are being tested in trial NCT04895189?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04895189?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI